Asset profile
SER-100
Small molecule
Evidence outlook · lead readout
NCT01987284 · Isolated Systolic Hypertension
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT01987284: The study was randomized, quadruple-blind, placebo-controlled, and used a crossover design, but it was small at 17 participants. Its primary clinical endpoint was the number of participants with adverse events, and no results are posted to show whether the comparison favored SER100.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.